Da	te: <u>September. 15<sup>th</sup>, 202</u>	22		
			(ad Nijalaan	-
Ma me	- ·	ide epigenetic and mRN corroborate the MIR14 ance in NSCLC cells	<b>Ad-Nielsen</b> A-expression profiling followed by CRISPR/Cas9- 1/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired	
rel par to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content on necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a o so.	
	e following questions apply inuscript only.	to the author's relationshi	ps/activities/interests as they relate to the current	
to		ension, you should declare	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensithe manuscript.	
	item #1 below, report all su e time frame for disclosure i		d in this manuscript without time limit. For all other it	ems,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	planning of the work	
L	All support for the present manuscript (e.g., funding, provision of study materials,	XNone		

	provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	
		Time frame: past 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone
3	Royalties or licenses	XNone

4 Consulting fees		
Consulting lees	XNone	
5 Payment or honoraria for	X None	
Payment or honoraria for lectures, presentations,	xnone	
speakers bureaus,		
manuscript writing or		
educational events		
Payment for expert testimony	XNone	
testimony		
7 Support for attending	XNone	
meetings and/or travel		
Detents planted issued = "	V. None	
Patents planned, issued or pending	XNone	
penamg		
9 Participation on a Data	X None	
Safety Monitoring Board or		
Advisory Board		
10 Leadership or fiduciary role	XNone	
in other board, society,	XNone	
* · · · · · · · · · · · · · · · · · · ·	XNone	
in other board, society, committee or advocacy	XNone	
in other board, society, committee or advocacy group, paid or unpaid		
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options	XNone	
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,		
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical	XNone	
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment,	XNone	
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other	XNone	
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	X_None	
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	X_None	
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	X_NoneX_NoneX_None	ollowing hox:
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-	X_NoneX_NoneX_None	ollowing box:
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests	X_NoneX_NoneX_None	ollowing box:
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests  Please summarize the above of	X_NoneX_NoneX_None	ollowing box:
in other board, society, committee or advocacy group, paid or unpaid  Stock or stock options  Receipt of equipment, materials, drugs, medical writing, gifts or other services  Other financial or non-financial interests  Please summarize the above of	X_NoneX_NoneX_None	ollowing box:

Date: September. 15<sup>th</sup>, 2022

in item #1 above).

Royalties or licenses

\_X\_\_None

You	r Name:	Nicklas Heine	Staunstrup		
med asso	diated gene ociated EGF	-disruptions o	corroborate the MIR14 nce in NSCLC cells	A-expression profiling followed by CRISPR/Cas9- 1/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired E	ЕМТ-
relat part to tr	ted to the co ies whose in ansparency	ntent of your m terests may be and does not no	nanuscript. "Related" me affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	following qu uscript only.		o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to the med	ne epidemiol lication, ever em #1 below	ogy of hyperten if that medica , report all sup	nsion, you should declare tion is not mentioned in	defined broadly. For example, if your manuscript pertai all relationships with manufacturers of antihypertensive the manuscript.  d in this manuscript without time limit. For all other ite	е
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
			Time frame: Since the initi	al planning of the work	
1	manuscript (opposition of smedical writing processing characteristics)	study materials, ing, article	XNone		
			Time frame: pas	st 36 months	
2	Grants or cor any entity (if	ntracts from not indicated	XNone		

4	Consulting fees	XNone	
_			
5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
10		V N	
12	Receipt of equipment,	X_None	_
	materials, drugs, medical writing, gifts or other		
	services		
4.0		V N	
13	Other financial or non- financial interests	XNone	
	ilitaticiai iliterests		
Plea	se summarize the above co	nflict of interest in the fo	llowing box:
N	one.		
Plea	se place an "X" next to the	following statement to in	ndicate your agreement:

form.

Date: September. 15 <sup>th</sup> , 2022	_
Your Name: Magnus Lindkvist Kjeldsen  Manuscript Title: Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9 mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired associated EGFR TKI-resistance in NSCLC cells  Manuscript number (if known): TLCR-22-507	
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.	
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .	
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript perta	ins

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive

medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Date: <u>Se</u>	ptember. 15 <sup></sup> , 2022
Your Name:	Nina Dybdal
Manuscript '	Title: Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-
C	gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT EGFR TKI-resistance in NSCLC cells
Manuscript	number (if known): <u>TLCR-22-507</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
_	0 16 11		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fo	Dilowing box:
	N		
	None.		
Ple	ease place an "X" next to the	e tollowing statement to i	ndicate your agreement:

form.

Date: September. 15 <sup>th</sup> , 2022				
Your Name:F_	ANDIN	Guillanne		
Manuscript Title: Geno	me-wide e	pigenetic and mRNA	A-expression profiling followed by CRISPR/Cas9-	
mediated gene-disru	ptions cor	roborate the MIR143	1/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-	
associated EGFR TKI-resistance in NSCLC cells				
Manuscript number (if	known): TLO	CR-22-507		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
or H		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
	P. S. Mitt. (Ellissa tox).	Time frame: pas	et 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X_None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
	8		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	X_None	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X_None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X_None	
	financial interests		
Ple	ase summarize the above co	onflict of interest in t	he following box:

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: September. 15 <sup>th</sup> , 2022				
Your Name: Claudia De Stradis				
Manuscript Title: Genome-wide epigenetic and mRNA-expression profiling followed by				
CRISPR/Cas9-mediated gene-disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis	in			
cquired EMT-associated EGFR TKI-resistance in NSCLC cells				
Manuscript number (if known): <u>TLCR-22-507</u>				
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.				

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from any	XNone	
	entity (if not indicated in		
	item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	X_None			
5	Payment or honoraria for	X None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options	X_None			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or	XNone			
	non-financial interests				
Ple	Please summarize the above conflict of interest in the following box:				
			-		

Nor	ne.		

Please place an "X" next to the following statement to indicate your agreement:

Date: September. 15<sup>th</sup>, 2022

in item #1 above).

Royalties or licenses

\_X\_\_None

You	r Name: <u>Tina Fuglsang</u>	Daugaard		
Mai me	nuscript Title: Genome-wid	le epigenetic and mRNA corroborate the MIR14 nce in NSCLC cells	A-expression profiling followed by CRISPR/Cas9- 1/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired I	
rela part to t	ted to the content of your m ties whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.	
	following questions apply to nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>	
to the med	he epidemiology of hyperter dication, even if that medica	nsion, you should declare tion is not mentioned in t port for the work reported	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive he manuscript.  d in this manuscript without time limit. For all other ite	/e
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated	XNone		

4	Consulting fees	XNone			
_					
5	Payment or honoraria for	XNone			
	lectures, presentations, speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	X None			
	testimony				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
10		V N			
12	Receipt of equipment,	X_None	_		
	materials, drugs, medical writing, gifts or other				
	services				
4.0		V N			
13	Other financial or non- financial interests	XNone			
	ilitaticiai iliterests				
Plea	se summarize the above co	nflict of interest in the fo	llowing box:		
N	None.				
Plea	se place an "X" next to the	following statement to in	ndicate your agreement:		

form.

Date: _	September. 15 <sup>th</sup> , 2022			
Your N	ame:	Trine Vilsbøll-Larsen		
Manus	cript Title:	Genome-wide epigenetic and mRNA-expression profiling followed by CRISPR/Cas9-		
media	ted gene-	disruptions corroborate the MIR141/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-		
associ	ated EGF	R TKI-resistance in NSCLC cells		
Manus	cript numb	per (if known): <u>TLCR-22-507</u>		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	No time innit for tims item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone			
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
_	educational events				
6	Payment for expert	XNone			
	testimony				
_	0 16 11				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	X_None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Ple	ease summarize the above c	onflict of interest in the fo	Dilowing box:		
	N				
	None.				
Ple	ease place an "X" next to the	e tollowing statement to i	ndicate your agreement:		

Dat	ate: September. 15 <sup>th</sup> , 2022	
Ma me	Christoffer Trier Maansson  Ianuscript Title: Genome-wide epigenetic and mRNA nediated gene-disruptions corroborate the MIR141 ssociated EGFR TKI-resistance in NSCLC cells Ianuscript number (if known): TLCR-22-507	-expression profiling followed by CRISPR/Cas9- /MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-
rela par to 1	the interest of transparency, we ask you to disclose all related to the content of your manuscript. "Related" mean arties whose interests may be affected by the content of transparency and does not necessarily indicate a bias. It	ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
	he following questions apply to the author's relationship nanuscript only.	s/activities/interests as they relate to the <u>current</u>
to 1	he author's relationships/activities/interests should be <u>d</u> o the epidemiology of hypertension, you should declare a nedication, even if that medication is not mentioned in th	all relationships with manufacturers of antihypertensive
	item #1 below, report all support for the work reported ne time frame for disclosure is the past 36 months.	in this manuscript without time limit. For all other items,
	whom you have this	Specifications/Comments (e.g., if payments were made to you or to your institution)

Time frame: past 36 months

All support for the present

manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)

No time limit for this item.

Grants or contracts from any entity (if not indicated

in item #1 above).

Royalties or licenses

3

X None

X None

\_X\_\_None

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events		
6	Payment for expert	XNone	
	testimony		
_	0 16 11		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other	X_None	
	services		
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	Dilowing box:
	Nana		
None.			
Ple	ease place an "X" next to the	e tollowing statement to i	ndicate your agreement:

form.

Your Name: Thomas Koed Doktor	
Manuscript Title: Genome-wide epigenetic and mRI	IA-expression profiling followed by CRISPR/Cas9-
mediated gene-disruptions corroborate the MIR1 associated EGFR TKI-resistance in NSCLC cells	41/MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT-
Manuscript number (if known): <u>TLCR-22-507</u>	

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	No time limit for this item.		
	no time initiation this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
6	educational events	V. Name	
ь	Payment for expert testimony	XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel		
	meetings and, or craver		
8	Patents planned, issued or	X None	
0	pending		
	penang		
_			
9	Participation on a Data	XNone	
	Safety Monitoring Board or Advisory Board		
10	•	V. None	
10	Leadership or fiduciary role in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
13	financial interests		
Ple	ase summarize the above co	onflict of interest in the fo	lowing box:
_			
	None.		
Ple	Please place an "X" next to the following statement to indicate your agreement:		

Date: September. 15 <sup>th</sup> , 2022
Your Name: Boe Sorensen
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

		V N	
4	Consulting fees	XNone	
5	Payment or honoraria for	XNone	
5	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
	meem ge and, as a second		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X_None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	Stock or stock options	XNone	
		V Ni	
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non- financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fo	ollowing box:
	None		
None.			
			I I

Please place an "X" next to the following statement to indicate your agreement:

Date: September. 16<sup>th</sup>, 2022

any entity (if not indicated

\_X\_\_None

in item #1 above).
Royalties or licenses

You	r Name: <u>Anders Lade N</u>	lielsen	
Mar med	nuscript Title: Genome-wic	le epigenetic and mRNA corroborate the MIR141 nce in NSCLC cells	a-expression profiling followed by CRISPR/Cas9- ./MIR200C-ZEB1/ZEB2-FGFR1 axis in acquired EMT
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ns any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment lf you are in doubt about whether to list a so.
	following questions apply to nuscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>
to tl		nsion, you should declare a	lefined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	<u> </u>	in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	l planning of the work
1	All support for the present	X None	
1	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)  No time limit for this item.		
	NO time limit for this item.		
		Time frame: past	26 months
2	Grants or contracts from	X None	- John Million Control of the Contro

4	Consulting fees	XNone	
_			
5	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	X None	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone	
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	XNone	
Plea	se summarize the above co	nflict of interest in the fo	llowing box:
N	one.		
Plea	se place an "X" next to the	following statement to in	ndicate your agreement: